-
Mashup Score: 18
Drs. Matthew Lee, Benjamin Levy, and Balazs Halmos say several key issues need to be addressed before this class of agents can achieve wider impact.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 18
Drs. Matthew Lee, Benjamin Levy, and Balazs Halmos say several key issues need to be addressed before this class of agents can achieve wider impact.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5FLAURA 2 Post-progression Outcomes Demonstrate Consistent Benefit, Favor Combination Arm - ILCN.org (ILCN/WCLC) - 1 month(s) ago
During the European Lung Cancer Congress, Dr. Natalia Valdiviezo presented the data, which favored frontline osimertinib plus chemotherapy compared to osimertinib alone for patients with EGFR-mutated NSCLC.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0US FDA Grants Breakthrough Therapy Designation for Novel TKI Targeting HER2, EGFR - ILCN.org (ILCN/WCLC) - 1 month(s) ago
The move was supported by preliminary evidence from a phase I, first-in-human study in patients with advanced NSCLC.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 19Should Biomarkers Be Used in the Clinical Management of ES-SCLC? - ILCN.org (ILCN/WCLC) - 1 month(s) ago
During a recent debate, Drs. Anne Chiang and Stephen Liu offered differing perspectives on the feasibility of biomarker use in the small-cell lung cancer space.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 12Experts Debate Addition of Frontline Chemotherapy for EGFR+ NSCLC - ILCN.org (ILCN/WCLC) - 1 month(s) ago
In light of data from FLAURA2 and MARIPOSA, Drs. Suresh Ramalingam and Joshua Sabari weighed the pros and cons during the 2024 TTLC meeting.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7Regulating Artificial Intelligence - ILCN.org (ILCN/WCLC) - 1 month(s) ago
The US FDA’s Dr. Harpreet Singh talks with ILCN about what the increasing use of AI means for the agency as it works to ensure drugs and devices are safe and effective.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Regulating Artificial Intelligence - ILCN.org (ILCN/WCLC) - 2 month(s) ago
The US FDA’s Dr. Harpreet Singh talks with ILCN about what the increasing use of AI means for the agency as it works to ensure drugs and devices are safe and effective.
Source: www.ilcn.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Regulating Artificial Intelligence - ILCN.org (ILCN/WCLC) - 2 month(s) ago
The US FDA’s Dr. Harpreet Singh talks with ILCN about what the increasing use of AI means for the agency as it works to ensure drugs and devices are safe and effective.
Source: www.ilcn.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0US FDA Approves Frontline Amivantamab Combination for Patients with EGFR exon 20 Insertion-mutated NSCLC - ILCN.org (ILCN/WCLC) - 2 month(s) ago
The agency also granted approval to amivantamab as a treatment for patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations who progressed on or after platinum-based chemotherapy.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
New commentary in #ILCN: ADCs provide a tremendous opportunity in NSCLC, but further refinement is still needed. Read more from Drs. Matthew Lee, Benjamin Levy, and Balazs Halmos: https://t.co/4qOhE1FJ1z @benlevylungdoc @DrSteveMartin #LCSM